Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci
- PMID: 27698005
- PMCID: PMC5065620
- DOI: 10.1093/aje/kww091
Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci
Erratum in
-
RE: "RISK PREDICTION FOR EPITHELIAL OVARIAN CANCER IN 11 UNITED STATES-BASED CASE-CONTROL STUDIES: INCORPORATION OF EPIDEMIOLOGIC RISK FACTORS AND 17 CONFIRMED GENETIC LOCI".Am J Epidemiol. 2017 Jul 1;186(1):130. doi: 10.1093/aje/kwx151. Am J Epidemiol. 2017. PMID: 28637302 Free PMC article. No abstract available.
Abstract
Previously developed models for predicting absolute risk of invasive epithelial ovarian cancer have included a limited number of risk factors and have had low discriminatory power (area under the receiver operating characteristic curve (AUC) < 0.60). Because of this, we developed and internally validated a relative risk prediction model that incorporates 17 established epidemiologic risk factors and 17 genome-wide significant single nucleotide polymorphisms (SNPs) using data from 11 case-control studies in the United States (5,793 cases; 9,512 controls) from the Ovarian Cancer Association Consortium (data accrued from 1992 to 2010). We developed a hierarchical logistic regression model for predicting case-control status that included imputation of missing data. We randomly divided the data into an 80% training sample and used the remaining 20% for model evaluation. The AUC for the full model was 0.664. A reduced model without SNPs performed similarly (AUC = 0.649). Both models performed better than a baseline model that included age and study site only (AUC = 0.563). The best predictive power was obtained in the full model among women younger than 50 years of age (AUC = 0.714); however, the addition of SNPs increased the AUC the most for women older than 50 years of age (AUC = 0.638 vs. 0.616). Adapting this improved model to estimate absolute risk and evaluating it in prospective data sets is warranted.
Keywords: genetic risk polymorphisms; model evaluation; ovarian cancer; risk model.
© The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Figures


References
-
- American Cancer Society Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society; 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/a.... Accessed September 14, 2016.
-
- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. - PubMed
-
- Freedman AN, Seminara D, Gail MH, et al. Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst. 2005;97(10):715–723. - PubMed
-
- Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–314. - PubMed
-
- Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250–1254. - PubMed
MeSH terms
Grants and funding
- U01 CA069417/CA/NCI NIH HHS/United States
- R01 CA080742/CA/NCI NIH HHS/United States
- R01 CA074850/CA/NCI NIH HHS/United States
- K07 CA092044/CA/NCI NIH HHS/United States
- P50 CA105009/CA/NCI NIH HHS/United States
- K07 CA080668/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- P30 CA076292/CA/NCI NIH HHS/United States
- R03 CA115195/CA/NCI NIH HHS/United States
- R01 CA076016/CA/NCI NIH HHS/United States
- K07 CA143047/CA/NCI NIH HHS/United States
- U19 CA148112/CA/NCI NIH HHS/United States
- P30 CA016359/CA/NCI NIH HHS/United States
- K07 CA095666/CA/NCI NIH HHS/United States
- N01 PC067010/PC/NCI NIH HHS/United States
- P50 CA159981/CA/NCI NIH HHS/United States
- P30 CA016056/CA/NCI NIH HHS/United States
- R01 CA087538/CA/NCI NIH HHS/United States
- P30 CA046592/CA/NCI NIH HHS/United States
- M01 RR000056/RR/NCRR NIH HHS/United States
- P30 CA072720/CA/NCI NIH HHS/United States
- R01 CA095023/CA/NCI NIH HHS/United States
- R03 CA113148/CA/NCI NIH HHS/United States
- R01 CA058598/CA/NCI NIH HHS/United States
- K22 CA138563/CA/NCI NIH HHS/United States
- R01 CA058860/CA/NCI NIH HHS/United States
- P30 CA014089/CA/NCI NIH HHS/United States
- R01 CA083918/CA/NCI NIH HHS/United States
- R01 CA054419/CA/NCI NIH HHS/United States
- R01 CA122443/CA/NCI NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- P01 CA017054/CA/NCI NIH HHS/United States
- N01 CN025403/CA/NCI NIH HHS/United States
- R01 CA112523/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
- R01 CA126841/CA/NCI NIH HHS/United States
- R01 CA094069/CA/NCI NIH HHS/United States